Icure Pharmaceutical Incorporation (175250) - Total Assets
Based on the latest financial reports, Icure Pharmaceutical Incorporation (175250) holds total assets worth ₩128.95 Billion KRW (≈ $87.38 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 175250 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Icure Pharmaceutical Incorporation - Total Assets Trend (2015–2024)
This chart illustrates how Icure Pharmaceutical Incorporation's total assets have evolved over time, based on quarterly financial data. Explore Icure Pharmaceutical Incorporation (175250) long-term investment share to see how much of total assets are deployed in long-term investments.
Icure Pharmaceutical Incorporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Icure Pharmaceutical Incorporation's total assets of ₩128.95 Billion consist of 41.5% current assets and 58.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩17.18 Billion | 12.9% |
| Accounts Receivable | ₩10.59 Billion | 8.0% |
| Inventory | ₩12.90 Billion | 9.7% |
| Property, Plant & Equipment | ₩64.53 Billion | 48.6% |
| Intangible Assets | ₩6.86 Billion | 5.2% |
| Goodwill | ₩1.60 Billion | 1.2% |
Asset Composition Trend (2015–2024)
This chart illustrates how Icure Pharmaceutical Incorporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Icure Pharmaceutical Incorporation (175250) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Icure Pharmaceutical Incorporation's current assets represent 41.5% of total assets in 2024, a decrease from 72.5% in 2015.
- Cash Position: Cash and equivalents constituted 12.9% of total assets in 2024, down from 53.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 48.6% of total assets.
Icure Pharmaceutical Incorporation Competitors by Total Assets
Key competitors of Icure Pharmaceutical Incorporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Icure Pharmaceutical Incorporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.71 | 0.71 | 1.71 |
| Quick Ratio | 0.71 | 0.57 | 1.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-20.39 Billion | ₩-27.24 Billion | ₩23.30 Billion |
Icure Pharmaceutical Incorporation - Advanced Valuation Insights
This section examines the relationship between Icure Pharmaceutical Incorporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.63 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -20.0% |
| Total Assets | ₩132.88 Billion |
| Market Capitalization | $54.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values Icure Pharmaceutical Incorporation's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Icure Pharmaceutical Incorporation's assets decreased by 20.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Icure Pharmaceutical Incorporation (2015–2024)
The table below shows the annual total assets of Icure Pharmaceutical Incorporation from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩132.88 Billion ≈ $90.05 Million |
-20.02% |
| 2023-12-31 | ₩166.14 Billion ≈ $112.59 Million |
-25.87% |
| 2022-12-31 | ₩224.12 Billion ≈ $151.88 Million |
+4.03% |
| 2021-12-31 | ₩215.45 Billion ≈ $146.01 Million |
+10.40% |
| 2020-12-31 | ₩195.15 Billion ≈ $132.25 Million |
-9.57% |
| 2019-12-31 | ₩215.80 Billion ≈ $146.24 Million |
+78.34% |
| 2018-12-31 | ₩121.00 Billion ≈ $82.00 Million |
+124.49% |
| 2017-12-31 | ₩53.90 Billion ≈ $36.53 Million |
+70.97% |
| 2016-12-31 | ₩31.53 Billion ≈ $21.36 Million |
+20.54% |
| 2015-12-31 | ₩26.15 Billion ≈ $17.72 Million |
-- |
About Icure Pharmaceutical Incorporation
Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks. In addition, the company provides … Read more